202 related articles for article (PubMed ID: 32429446)
1. Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and Possible Biochemical Pathways.
Di Gilio A; Catino A; Lombardi A; Palmisani J; Facchini L; Mongelli T; Varesano N; Bellotti R; Galetta D; de Gennaro G; Tangaro S
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429446
[TBL] [Abstract][Full Text] [Related]
2. Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study.
Lamote K; Brinkman P; Vandermeersch L; Vynck M; Sterk PJ; Van Langenhove H; Thas O; Van Cleemput J; Nackaerts K; van Meerbeeck JP
Oncotarget; 2017 Oct; 8(53):91593-91602. PubMed ID: 29207669
[TBL] [Abstract][Full Text] [Related]
3. Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure.
de Gennaro G; Dragonieri S; Longobardi F; Musti M; Stallone G; Trizio L; Tutino M
Anal Bioanal Chem; 2010 Dec; 398(7-8):3043-50. PubMed ID: 20924566
[TBL] [Abstract][Full Text] [Related]
4. Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS).
Lamote K; Vynck M; Van Cleemput J; Thas O; Nackaerts K; van Meerbeeck JP
J Breath Res; 2016 Sep; 10(4):046001. PubMed ID: 27669062
[TBL] [Abstract][Full Text] [Related]
5. Exhaled breath to screen for malignant pleural mesothelioma: a validation study.
Lamote K; Vynck M; Thas O; Van Cleemput J; Nackaerts K; van Meerbeeck JP
Eur Respir J; 2017 Dec; 50(6):. PubMed ID: 29269578
[TBL] [Abstract][Full Text] [Related]
6. An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls.
Dragonieri S; van der Schee MP; Massaro T; Schiavulli N; Brinkman P; Pinca A; Carratú P; Spanevello A; Resta O; Musti M; Sterk PJ
Lung Cancer; 2012 Mar; 75(3):326-31. PubMed ID: 21924516
[TBL] [Abstract][Full Text] [Related]
7. Headspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lines as Translational Bridge for Breath Research.
Janssens E; Mol Z; Vandermeersch L; Lagniau S; Vermaelen KY; van Meerbeeck JP; Walgraeve C; Marcq E; Lamote K
Front Oncol; 2022; 12():851785. PubMed ID: 35600344
[TBL] [Abstract][Full Text] [Related]
8. Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.
Töreyin ZN; Ghosh M; Göksel Ö; Göksel T; Godderis L
Int J Environ Res Public Health; 2020 Feb; 17(3):. PubMed ID: 32050546
[TBL] [Abstract][Full Text] [Related]
9. External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma.
Janssens E; Schillebeeckx E; Zwijsen K; Raskin J; Van Cleemput J; Surmont VF; Nackaerts K; Marcq E; van Meerbeeck JP; Lamote K
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804954
[TBL] [Abstract][Full Text] [Related]
10. Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.
Brusselmans L; Arnouts L; Millevert C; Vandersnickt J; van Meerbeeck JP; Lamote K
Transl Lung Cancer Res; 2018 Oct; 7(5):520-536. PubMed ID: 30450290
[TBL] [Abstract][Full Text] [Related]
11. Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma.
Catino A; de Gennaro G; Di Gilio A; Facchini L; Galetta D; Palmisani J; Porcelli F; Varesano N
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31207975
[TBL] [Abstract][Full Text] [Related]
12. Calculated indices of volatile organic compounds (VOCs) in exhalation for lung cancer screening and early detection.
Chen X; Muhammad KG; Madeeha C; Fu W; Xu L; Hu Y; Liu J; Ying K; Chen L; Yurievna GO
Lung Cancer; 2021 Apr; 154():197-205. PubMed ID: 33653598
[TBL] [Abstract][Full Text] [Related]
13. Analysis of volatile organic compounds in the breath of patients with stable or acute exacerbation of chronic obstructive pulmonary disease.
Pizzini A; Filipiak W; Wille J; Ager C; Wiesenhofer H; Kubinec R; Blaško J; Tschurtschenthaler C; Mayhew CA; Weiss G; Bellmann-Weiler R
J Breath Res; 2018 Mar; 12(3):036002. PubMed ID: 29295966
[TBL] [Abstract][Full Text] [Related]
14. Determining the clinical utility of a breath test for screening an asbestos-exposed population for pleural mesothelioma: baseline results.
Zwijsen K; Schillebeeckx E; Janssens E; Cleemput JV; Richart T; Surmont VF; Nackaerts K; Marcq E; van Meerbeeck JP; Lamote K
J Breath Res; 2023 Sep; 17(4):. PubMed ID: 37683624
[TBL] [Abstract][Full Text] [Related]
15. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
16. Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure.
Watzka SB; Posch F; Pass HI; Flores RM; Hannigan GE; Bernhard D; Weber M; Mueller MR
Eur J Cardiothorac Surg; 2013 May; 43(5):940-5. PubMed ID: 23045294
[TBL] [Abstract][Full Text] [Related]
17. Effects of Curative Colorectal Cancer Surgery on Exhaled Volatile Organic Compounds and Potential Implications in Clinical Follow-up.
Altomare DF; Di Lena M; Porcelli F; Travaglio E; Longobardi F; Tutino M; Depalma N; Tedesco G; Sardaro A; Memeo R; de Gennaro G
Ann Surg; 2015 Nov; 262(5):862-6; discussion 866-7. PubMed ID: 26583677
[TBL] [Abstract][Full Text] [Related]
18. Investigation of different approaches for exhaled breath and tumor tissue analyses to identify lung cancer biomarkers.
Gashimova E; Temerdashev A; Porkhanov V; Polyakov I; Perunov D; Azaryan A; Dmitrieva E
Heliyon; 2020 Jun; 6(6):e04224. PubMed ID: 32577579
[TBL] [Abstract][Full Text] [Related]
19. Clustering of malignant pleural mesothelioma in asbestos factories: a subgroup analysis in a 29-year follow-up study to identify high-risk industries in Taiwan.
Lee LJ; Lin CK; Pan CH; Cheng Y; Chang YY; Liou SH; Wang JD
BMJ Open; 2018 Dec; 8(12):e021063. PubMed ID: 30530573
[TBL] [Abstract][Full Text] [Related]
20. Confounding effect of benign pulmonary diseases in selecting volatile organic compounds as markers of lung cancer.
Wang M; Sheng J; Wu Q; Zou Y; Hu Y; Ying K; Wan H; Wang P
J Breath Res; 2018 Sep; 12(4):046013. PubMed ID: 30102249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
